Tianyu now has more than 14,000 square metres of research use area and 100 million yuan of investment in research instruments and equipment. Tianyu continues to increase R&D investment, R&D investment of 276 million yuan in 2023, accounting for 10.92% of revenue. The R&D team consists of nearly 500 people, of which more than 100 have master's and doctoral degrees.

The main R&D direction involves blood pressure-lowering, blood sugar-lowering, lipid-lowering, anti-coagulation, anti-asthma, anti-virus, anti-tumour, anti-heart failure, anti-epileptic, gout, anti-prostate hyperplasia and so on. Our core technologies include grignard reaction technology, diazotisation technology, asymmetric reduction technology and heterocyclic compound synthesis.

At present, Tianyu has 109 authorized patents, including 51 national authorized invention patents, 12 authorized invention patents from the United States, Europe, Japan, India and other countries, and 46 utility model patents: 32 invention patents are in the application stage, and the number of patent applications increases by 8-12 per year.